A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

• Main Authors: Yuanyuan Sun (Author), Heng Yang (Author), Xiaoyan Yang (Author), Shuang Yang (Author), Can Guo (Author), Honghui Chen (Author), Chang Cui (Author), Yuxia Xiang (Author), Guoping Yang (Author), Jie Huang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: This is the first study to compare the pharmacokinetics, safety and, immunogenicity of QL1209, a biosimilar of Perjeta®.Methods: This study was a randomized, double-blind, parallel-controlled clinical trial evaluating the biosimilarity between QL1209 (specification: 420 mg:14 ml, single use...